Princeton Public Schools

An Interval-Certified Positivity Block at c=13 for an Odd Pole-Free Riemann Reduction

We establish positivity of the canonical localized pole-free odd closed form at the fixed support parameter c=13. The proof combines an exact arithmetic-source identification, a uniform high-diagonal Schur transfer, finite interval-certified elimination, and a corrected enclosure...

A Rigorous Finite-Dimensional Verifier for an Odd Pole-Free Riemann Positivity Criterion

We develop a rigorous numerical verification framework for a finite-dimensional positivity problem arising from an odd, pole-free formulation connected to the Riemann hypothesis. The computational objective is not to infer positivity from floating-point evidence, but to certify e...

A Game-Theoretic Assessment of Optimal Strategies in Artificial Intelligence Competition Between the United States and China

Semiquantitative analysis was done to ascertain the extent of the difference between the United States and China. This paper analyzes the competition between the United States(US) and China in artificial intelligence(AI) and uses game theory to examine its impact on US-China econ...

A Game-Theoretic Assessment of Optimal Strategies in Artificial Intelligence Competition Between the United States and China

Semiquantitative analysis was done to ascertain the extent of the difference between the United States and China. This paper analyzes the competition between the United States(US) and China in artificial intelligence(AI) and uses game theory to examine its impact on US-China econ...

Bridging the social license gap: How community-directed communication shapes risk perception and acceptance of carbon capture and storage in the United States

Achieving global climate targets demands rapid deployment of new technologies, yet technological readiness risks outpacing the social license needed for deployment. Carbon capture and storage (CCS) exemplifies this challenge: deployment is expanding rapidly, but public awareness...

Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)

Objectives PsA affects ~20-30% of patients with PsO, causing articular inflammation and impaired quality of life. ICO, a novel targeted oral peptide that binds IL-23 receptor, showed greater clinical response rates vs placebo and a favorable safety profile in moderate-to-severe p...